Javascript must be enabled to continue!
Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity
View through CrossRef
AbstractProtamine sulfate blocked 125I‐PDGF binding to its specific physiological receptor on Swiss mouse 3T3 cells. Reduced 125I‐PDGF binding in the presence of protamine sulfate correlated directly with a protamine sulfate dose‐dependent decrease in the PDGF‐dependent incorporation of [3H]‐thymidine into 3T3 cells and a decreased PDGF‐stimulated tyrosine‐specific protein kinase activity in isolated membrane preparations of 3T3 cells. Protamine sulfate blocked 125I‐PDGF binding to simian sarcoma virus transformed cells (SSV‐NIH 3T3 and SSV‐NPl cells) and to nontransformed cells in a manner qualitatively identical to unlabelled PDGF. In contrast, protamine sulfate enhanced the specific binding of 125I‐EGF by increasing the apparent number of EGF receptors on the cell surface. The increase in 125I‐EGF receptor binding was not prevented by cycloheximide nor by actinomycin D. Protamine sulfate did not affect 125I‐EGF binding to membranes from 3T3 cells or the EGF‐stimulated 3T3 cell membrane tyrbsinc specific protein kinase activity, suggesting that protamine sulfate may have exposed a population of cryptic EGF receptors otherwise not accessible. Protamine sulfate was fractionated into four active fractions by Sephadex G‐50 gel filtration columns; the half maximum inhibition concentration of 125I‐PDGF binding to 3T3 cells of protamines I and II (MW ∼ 11,000 daltons and 7,000 daltons, respectively) is ∼ 0.4 μM. Protamine II (MW ∼ 4,800 daltons) was equally active (half maximum inhibition concentration ∼ 0.4 μM); protamine IV (MW ∼ 3,300 daltons) was substantially less active (half maximum inhibition concentration ∼ 2.8 μM).These investigations have extended previous observations that protamine sulfate is a potent inhibitor of PDGF binding and establish that protamine sulfate blocks PDGF binding at the physiological receptor, preventing PDGF initiated biological activities. Protamine sulfate can be used as a reagent to separate the influence of PDGF and EGF on cells with high specificity and has been used to demonstrate that the receptors on simian sarcoma virus transformed 3T3 cells qualitatively respond identically to protamine sulfate as to unlabelled PDGF and are likely identical to those on nontransformed 3T3 cells.
Title: Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity
Description:
AbstractProtamine sulfate blocked 125I‐PDGF binding to its specific physiological receptor on Swiss mouse 3T3 cells.
Reduced 125I‐PDGF binding in the presence of protamine sulfate correlated directly with a protamine sulfate dose‐dependent decrease in the PDGF‐dependent incorporation of [3H]‐thymidine into 3T3 cells and a decreased PDGF‐stimulated tyrosine‐specific protein kinase activity in isolated membrane preparations of 3T3 cells.
Protamine sulfate blocked 125I‐PDGF binding to simian sarcoma virus transformed cells (SSV‐NIH 3T3 and SSV‐NPl cells) and to nontransformed cells in a manner qualitatively identical to unlabelled PDGF.
In contrast, protamine sulfate enhanced the specific binding of 125I‐EGF by increasing the apparent number of EGF receptors on the cell surface.
The increase in 125I‐EGF receptor binding was not prevented by cycloheximide nor by actinomycin D.
Protamine sulfate did not affect 125I‐EGF binding to membranes from 3T3 cells or the EGF‐stimulated 3T3 cell membrane tyrbsinc specific protein kinase activity, suggesting that protamine sulfate may have exposed a population of cryptic EGF receptors otherwise not accessible.
Protamine sulfate was fractionated into four active fractions by Sephadex G‐50 gel filtration columns; the half maximum inhibition concentration of 125I‐PDGF binding to 3T3 cells of protamines I and II (MW ∼ 11,000 daltons and 7,000 daltons, respectively) is ∼ 0.
4 μM.
Protamine II (MW ∼ 4,800 daltons) was equally active (half maximum inhibition concentration ∼ 0.
4 μM); protamine IV (MW ∼ 3,300 daltons) was substantially less active (half maximum inhibition concentration ∼ 2.
8 μM).
These investigations have extended previous observations that protamine sulfate is a potent inhibitor of PDGF binding and establish that protamine sulfate blocks PDGF binding at the physiological receptor, preventing PDGF initiated biological activities.
Protamine sulfate can be used as a reagent to separate the influence of PDGF and EGF on cells with high specificity and has been used to demonstrate that the receptors on simian sarcoma virus transformed 3T3 cells qualitatively respond identically to protamine sulfate as to unlabelled PDGF and are likely identical to those on nontransformed 3T3 cells.
Related Results
PATHOPHYSIOLOGY OF THROMBOCYTOPENIA AND RESULTANT CLINICAL INDICATIONS FOR PLATELET TRANSFUSION
PATHOPHYSIOLOGY OF THROMBOCYTOPENIA AND RESULTANT CLINICAL INDICATIONS FOR PLATELET TRANSFUSION
Careful evaluation of platelet survival data in normal individuals and patients with thrombocytopeniasecondary to marrow aplasia has demonstrated that platelets are lost from circu...
Heparin-protamine management: a comparison study of three different heparin-protamine management protocols
Heparin-protamine management: a comparison study of three different heparin-protamine management protocols
In a prospective randomized open study, 180 patients underwent open-heart surgery using cardiopulmonary bypass (CPB) and were divided into three different heparin-protamine managem...
Optimal Protamine Dosing for Heparin Reversal in Cardiopulmonary Bypass: A Quasi-Experimental Study in Elective Coronary Artery Bypass Surgery
Optimal Protamine Dosing for Heparin Reversal in Cardiopulmonary Bypass: A Quasi-Experimental Study in Elective Coronary Artery Bypass Surgery
Objectives: Protamine sulfate is routinely administered after cardiopulmonary bypass (CPB) to neutralize heparin; however, conventional 1:1 heparin–protamine dosing may exceed the ...
Abstract 2667: Platelet microparticles infiltrating solid tumors transfer miRNAs and modulate tumor angiogenesis and growth
Abstract 2667: Platelet microparticles infiltrating solid tumors transfer miRNAs and modulate tumor angiogenesis and growth
Abstract
Platelet-derived microparticles are associated with enhancement of metastasis and poor cancer outcomes. Platelet microparticles can transfer platelet microR...
Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins
Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins
Plasma and platelet factor Va represent different substrates for activated protein C (APC). In this study, we have measured platelet-dependent APC resistance and the effect of aspi...
Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins
Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins
AbstractPlasma and platelet factor Va represent different substrates for activated protein C (APC). In this study, we have measured platelet-dependent APC resistance and the effect...
Autoimmune thrombocytopenic purpura
Autoimmune thrombocytopenic purpura
Adult autoimmune throbocytopenic purpura (ATP) is a platelet disorder that develops in certain individuals with a genetic as well as sex (female) predisposition following an enviro...
Autoimmune thrombocytopenic purpura
Autoimmune thrombocytopenic purpura
Abstract
Adult autoimmune throbocytopenic purpura (ATP) is a platelet disorder that develops in certain individuals with a genetic as well as sex (female) predisposi...

